Hyperviscosity in HIV infected children--a potential hazard during intravenous immunoglobulin therapy. NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Hyperviscosity in HIV infected children--a potential hazard during intravenous immunoglobulin therapy.

Blut. 1990 Aug-Sep;61(2-3):66-7. Unique Identifier : AIDSLINE MED/91002940
Hague RA; Eden OB; Yap PL; Mok JY; Rae P; Edinburgh and SE Scotland Blood Transfusion Service, UK.

Abstract: A four year old boy with symptoms of HIV infection and serum IgG of 53.2 g/l had been treated for 16 months with regular infusions of intravenous immunoglobulin (IV IgG). During one such infusion he developed temporary neurological symptoms and signs suggestive of the hyperviscosity syndrome. Serum relative viscosity was raised at 5.0 (normal range 0.42-2.78). Subsequent IV IgG infusions given at a slower rate have been without adverse reactions. In a study of eight HIV infected children including the index case, and 20 children not infected with HIV, serum relative viscosity was significantly raised in the HIV infected children (p less than 0.01; students t-test). Viscosity correlated with total serum IgG, which was raised in all HIV infected children, and with serum IgM. In HIV infected children with very high levels of serum IgG a slow rate of IV IgG infusion should therefore be chosen due to the possibility of hyperviscosity.
Keywords: *Blood Viscosity Case Report Child, Preschool Human HIV Infections/*BLOOD IgG/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Infant Infusions, Intravenous Male Support, Non-U.S. Gov't JOURNAL ARTICLEKWDbloodviscositycasereportchild,preschoolhumanhivinfections/KWDbloodigg/administration&dosage/therapeuticuseinfantinfusions,intravenousmalesupport,non-uKWDsKWDgov'tjournalarticle
910130
M9110562

Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .